Drugs 2006; 66 (5): 607-624
نویسندگان
چکیده
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 607 1. Restless Legs Syndrome (RLS) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 608 1.1 Diagnosis of RLS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 608 1.2 Epidemiology of RLS in Patients with Chronic Kidney Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609 1.3 Pathogenesis of RLS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 610 2. Treatment of RLS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611 2.1 Nonpharmacological Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611 2.2 Correction of Anaemia and Iron Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611 2.3 Dopaminergic Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 613 2.3.1 Levodopa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 613 2.3.2 Dopamine Agonists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 613 2.3.3 Augmentation and Rebound . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 617 2.4 Nondopaminergic Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 617 2.4.1 Gabapentin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 617 2.4.2 Benzodiazepines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618 2.4.3 Opioids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618 2.4.4 Other Medications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619 3. Overall Treatment Recommendation for Dialysis Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619 Restless legs syndrome (RLS) is characterised by an urge to move the legs, Abstract uncomfortable sensations in the legs and worsening of these symptoms during rest with at least temporary relief brought on by activity. RLS occurs in 3–15% of the general population and in 10–30% of patients on maintenance dialysis. RLS may lead to severe sleep onset or maintenance insomnia, and greatly impaired quality
منابع مشابه
Analysis of polymorphisms of the interleukin-18 gene in type 1 diabetes and Hardy-Weinberg equilibrium testing.
Recently, the interleukin-18 cytokine gene (IL18) was reported to be associated with type 1 diabetes. In the present report, we calculated that the reported genotypes of the two 5' region/promoter single nucleotide polymorphisms (SNPs), -607 (C-->A) (rs1946518) and -137 (G-->C) (rs187238), were not in Hardy-Weinberg equilibrium (HWE). We therefore investigated the association of the -607 and -1...
متن کاملCNS Drugs 2012;
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601 1. Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602 2. Receptor Affinity. . . . . . . . . . . . . . . . . . . . . . . ....
متن کاملGlobal Justice in Healthcare: Developing Drugs for the Developing World
TABLE OF CONTENTS INTRODUCTION ................................................................................... 583 I. REASONS................................................................................... 585 A. National Self-Interest......................................................... 588 B. Historical Equity ............................................................... 591 C. S...
متن کاملEnterobacterial common antigen.
INTRODUCTION .............. ................................ 591 DISCOVERY AND DEFINITIONS ............................................. 591 SEROLOGICAL METHODS ............................................. 592 Hemagglutination (HA), Hemolysis, and Hemagglutination Inhibition (HAI) ... 592 Other Serological Methods ............................................. 593 CHEMISTRY .......................
متن کاملThe bacterial photosynthetic reaction center as a model for membrane proteins.
PERSPECTIVES AND SUMMARY .............................................................. 607 INTRODUCTION ..................................................................................... 609 Notation ............................................................................................. 610 STRUCTURE OF THE RC ......................................................................... 6...
متن کامل